BR112022025141A2 - Fabricação, formulação e dosagem de apraglutida - Google Patents

Fabricação, formulação e dosagem de apraglutida

Info

Publication number
BR112022025141A2
BR112022025141A2 BR112022025141A BR112022025141A BR112022025141A2 BR 112022025141 A2 BR112022025141 A2 BR 112022025141A2 BR 112022025141 A BR112022025141 A BR 112022025141A BR 112022025141 A BR112022025141 A BR 112022025141A BR 112022025141 A2 BR112022025141 A2 BR 112022025141A2
Authority
BR
Brazil
Prior art keywords
apraglutida
dosage
formulation
manufacture
formulating
Prior art date
Application number
BR112022025141A
Other languages
English (en)
Inventor
Feldman Gleb
Bolognani Federico
Original Assignee
Vectivbio Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectivbio Ag filed Critical Vectivbio Ag
Publication of BR112022025141A2 publication Critical patent/BR112022025141A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Preventing Unauthorised Actuation Of Valves (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FABRICAÇÃO, FORMULAÇÃO E DOSAGEM DE APRAGLUTIDA. A presente invenção refere-se a métodos de produção, formulação e administração de análogos de GLP-2.
BR112022025141A 2020-06-09 2021-06-09 Fabricação, formulação e dosagem de apraglutida BR112022025141A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063036507P 2020-06-09 2020-06-09
US202063074119P 2020-09-03 2020-09-03
US202163157083P 2021-03-05 2021-03-05
PCT/US2021/036655 WO2021252659A1 (en) 2020-06-09 2021-06-09 Manufacture, formulation and dosing of apraglutide

Publications (1)

Publication Number Publication Date
BR112022025141A2 true BR112022025141A2 (pt) 2023-04-25

Family

ID=76731091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025141A BR112022025141A2 (pt) 2020-06-09 2021-06-09 Fabricação, formulação e dosagem de apraglutida

Country Status (11)

Country Link
US (4) US20220000985A1 (pt)
EP (1) EP4161553A1 (pt)
JP (3) JP2023529478A (pt)
KR (1) KR20230038187A (pt)
CN (1) CN116157413A (pt)
AU (1) AU2021286563A1 (pt)
BR (1) BR112022025141A2 (pt)
CA (1) CA3182260A1 (pt)
IL (1) IL298964A (pt)
MX (1) MX2022015684A (pt)
WO (1) WO2021252659A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518192A (zh) * 2020-05-26 2020-08-11 成都圣诺生物制药有限公司 一种Apraglutide的制备方法
KR20230038187A (ko) 2020-06-09 2023-03-17 벡티브바이오 에이지 아프라글루타이드의 제조, 제형화 및 투여
AU2022212119A1 (en) 2021-01-28 2023-08-10 Vectivbio Ag Compositions and methods for the treatment of graft versus host disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
JP5197012B2 (ja) 2004-11-01 2013-05-15 エヌピーエス ファーマシューティカルズ インコーポレイテッド 大腸連続性を伴う短腸症候群患者の治療
EP2295451A1 (en) 2005-05-04 2011-03-16 Zealand Pharma A/S Glucagon-like-peptide (GLP-2) analogues
US8589918B1 (en) 2007-03-21 2013-11-19 Moka5, Inc. Multi-platform compatible portable virtual machine player
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
JP5908478B2 (ja) 2010-08-30 2016-04-26 エヌピーエス ファーマシューティカルズ インコーポレイテッドＮｐｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
DE102011013792A1 (de) 2011-03-03 2012-09-06 Vetter Pharma-Fertigung GmbH & Co. KG Verschluss für eine Pulverspritze und Pulverspritze
AU2013255752B2 (en) 2012-05-03 2017-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
WO2018157131A1 (en) 2017-02-27 2018-08-30 Urigen N.A. Treatment of lower urinary tract epithelium with glucagon like peptide 2
WO2019066586A1 (ko) 2017-09-28 2019-04-04 한미약품 주식회사 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체
CN112057607A (zh) 2019-06-10 2020-12-11 苏州兰鼎生物制药有限公司 一种胰高血糖素样肽-2或其类似物的口服药物组合物
CN111329995B (zh) 2020-02-18 2022-11-11 河南中医药大学 Glp-2类似物在制备防治pd药物中的应用及防治pd的药物
CN111518192A (zh) 2020-05-26 2020-08-11 成都圣诺生物制药有限公司 一种Apraglutide的制备方法
KR20230038187A (ko) 2020-06-09 2023-03-17 벡티브바이오 에이지 아프라글루타이드의 제조, 제형화 및 투여

Also Published As

Publication number Publication date
US20230241179A1 (en) 2023-08-03
US20230173033A1 (en) 2023-06-08
WO2021252659A8 (en) 2022-02-17
JP2023134516A (ja) 2023-09-27
MX2022015684A (es) 2023-02-27
JP2023529478A (ja) 2023-07-10
US11766470B2 (en) 2023-09-26
US20220062384A1 (en) 2022-03-03
CN116157413A (zh) 2023-05-23
US20220000985A1 (en) 2022-01-06
EP4161553A1 (en) 2023-04-12
CA3182260A1 (en) 2021-12-16
JP2023138964A (ja) 2023-10-03
KR20230038187A (ko) 2023-03-17
IL298964A (en) 2023-02-01
WO2021252659A1 (en) 2021-12-16
AU2021286563A1 (en) 2023-01-19
JP7425916B2 (ja) 2024-01-31

Similar Documents

Publication Publication Date Title
BR112022025141A2 (pt) Fabricação, formulação e dosagem de apraglutida
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CL2022003711A1 (es) Derivados de quinoxalina como fármacos contra el cáncer
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
CY1120213T1 (el) Antαγωνιστες φθοριωμενης ιντεγκρινης
CR20180232A (es) Macrociclos peptídicos contra acinetobacter baumannii
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
CO2020001927A2 (es) Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
MX2019007641A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
CO2021007453A2 (es) Conjugados de insulina
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
AR116451A1 (es) Administración oral de análogos del péptido glp-1
BR112022010419A2 (pt) Tratamento de hipoparatireoidismo
MY191895A (en) Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
BR112023022755A2 (pt) Composto cíclico possuindo efeito inibidor seletivo para kras, mas não para hras e nras
BR112023000220A2 (pt) Formulações de longa ação
BR112022000914A2 (pt) Composição farmacêutica
BR112021019903A2 (pt) Composição farmacêutica aquosa, uso da composição farmacêutica aquosa e método de produção de uma composição farmacêutica aquosa
CL2020000508A1 (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.
BR112018069782A2 (pt) composição farmacêutica de dapagliflozina
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização